Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31
|
EQS-News: M1 Kliniken AG
/ Key word(s): Quarter Results/Quarterly / Interim Statement
M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31 Berlin, 5 June 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) has made a strong start to the 2025 financial year and continues its profitable growth trajectory. The significant improvement in earnings results from the consistent implementation of efficiency measures and the targeted expansion of medical capacities. Key Financials at a Glance
Beauty Segment: Profitability Further Increased
The Beauty segment remains the Group’s main earnings driver. In Q1, it benefited in particular from efficiency gains through optimized processes and higher utilization of medical capacity. A targeted pricing strategy helped attract new customer groups and support market share expansion, without impacting margin quality. M1 continues to pursue its positioning as a leading provider of high-quality aesthetic medicine at market-leading prices. Trading Segment: Double-Digit Growth in Revenue and EBIT
The trading segment continued its positive development in Q1, once again posting double-digit growth in both revenue and EBIT. Segment profitability was further improved. Outlook In 2025, M1 Kliniken AG aims to continue its profitable growth by expanding its network of national and international clinics. In the Beauty segment, full-year revenue is expected to range between EUR 100 million and EUR 120 million. By 2029, this figure is projected to grow to EUR 200 million to EUR 300 million, with a sustainably targeted EBIT margin of at least 20%. The Group is consistently pursuing its goal of establishing M1 Med Beauty as the world’s leading brand in aesthetic medicine. M1’s business activities remain unaffected by current geopolitical developments, as the Group has neither operational sites nor supply or service relationships in the affected regions. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardization, and consistent scalability, the Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
05.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2151076 |
| End of News | EQS News Service |
|
|
2151076 05.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.